Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra

Manuel Alfredo Podestà; Giorgio Graziani; Francesco Reggiani; Michele Buemi; Salvatore Badalamenti; Claudio Ponticelli

doi:10.1016/j.krcp.2014.07.007

Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra

Manuel Alfredo Podestà, Giorgio Graziani, Francesco Reggiani, Michele Buemi, Salvatore Badalamenti, Claudio Ponticelli

Istituto Clinico Humanitas

Research output: Contribution to journal › Article › peer-review

Abstract

Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by infiltrates of lipid-laden CD68⁺/CD1a^- histiocytes, affecting heart, lungs, central nervous system, and bones. Kidney and adjacent structures can also be affected, leading to renal failure in about 30% of cases. The diagnosis is challenging, and treatment is generally based on administration of interferon-alpha (IFNα), but preliminary results also showed the therapeutic efficacy of anakinra, an antagonist of the receptor of interleukin-1 (IL-1). We report the case of an elderly patient with ECD and severe involvement of the heart and kidneys who was successfully treated with anakinra.

Original language	English
Pages (from-to)	165-167
Number of pages	3
Journal	Kidney Research and Clinical Practice
Volume	33
Issue number	3
DOIs	https://doi.org/10.1016/j.krcp.2014.07.007
Publication status	Published - Sep 1 2014

Keywords

Anakinra
Erdheim-Chester disease
Renal failure

ASJC Scopus subject areas

Nephrology

Access to Document

10.1016/j.krcp.2014.07.007

Cite this

@article{75e4484ac26e4930a606f5c436813d01,

title = "Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra",

abstract = "Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by infiltrates of lipid-laden CD68+/CD1a- histiocytes, affecting heart, lungs, central nervous system, and bones. Kidney and adjacent structures can also be affected, leading to renal failure in about 30% of cases. The diagnosis is challenging, and treatment is generally based on administration of interferon-alpha (IFNα), but preliminary results also showed the therapeutic efficacy of anakinra, an antagonist of the receptor of interleukin-1 (IL-1). We report the case of an elderly patient with ECD and severe involvement of the heart and kidneys who was successfully treated with anakinra.",

keywords = "Anakinra, Erdheim-Chester disease, Renal failure",

author = "Podest{\`a}, {Manuel Alfredo} and Giorgio Graziani and Francesco Reggiani and Michele Buemi and Salvatore Badalamenti and Claudio Ponticelli",

year = "2014",

month = sep,

day = "1",

doi = "10.1016/j.krcp.2014.07.007",

language = "English",

volume = "33",

pages = "165--167",

journal = "Kidney Research and Clinical Practice",

issn = "2211-9132",

publisher = "Elsevier Korea",

number = "3",

}

TY - JOUR

T1 - Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra

AU - Podestà, Manuel Alfredo

AU - Graziani, Giorgio

AU - Reggiani, Francesco

AU - Buemi, Michele

AU - Badalamenti, Salvatore

AU - Ponticelli, Claudio

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by infiltrates of lipid-laden CD68+/CD1a- histiocytes, affecting heart, lungs, central nervous system, and bones. Kidney and adjacent structures can also be affected, leading to renal failure in about 30% of cases. The diagnosis is challenging, and treatment is generally based on administration of interferon-alpha (IFNα), but preliminary results also showed the therapeutic efficacy of anakinra, an antagonist of the receptor of interleukin-1 (IL-1). We report the case of an elderly patient with ECD and severe involvement of the heart and kidneys who was successfully treated with anakinra.

AB - Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by infiltrates of lipid-laden CD68+/CD1a- histiocytes, affecting heart, lungs, central nervous system, and bones. Kidney and adjacent structures can also be affected, leading to renal failure in about 30% of cases. The diagnosis is challenging, and treatment is generally based on administration of interferon-alpha (IFNα), but preliminary results also showed the therapeutic efficacy of anakinra, an antagonist of the receptor of interleukin-1 (IL-1). We report the case of an elderly patient with ECD and severe involvement of the heart and kidneys who was successfully treated with anakinra.

KW - Anakinra

KW - Erdheim-Chester disease

KW - Renal failure

UR - http://www.scopus.com/inward/record.url?scp=84907875298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907875298&partnerID=8YFLogxK

U2 - 10.1016/j.krcp.2014.07.007

DO - 10.1016/j.krcp.2014.07.007

M3 - Article

AN - SCOPUS:84907875298

VL - 33

SP - 165

EP - 167

JO - Kidney Research and Clinical Practice

JF - Kidney Research and Clinical Practice

SN - 2211-9132

IS - 3

ER -

Improvement of Erdheim-Chester disease-related renal failure after treatment with anakinra

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this